Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04543071 |
|
Recruitment Status :
Recruiting
First Posted : September 9, 2020
Last Update Posted : February 28, 2024
|
Sponsor:
Gulam Manji
Collaborators:
Regeneron Pharmaceuticals
BioLine Rx
Information provided by (Responsible Party):
Gulam Manji, Columbia University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | July 2025 |
| Estimated Study Completion Date : | August 2025 |